Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (NPC)
Shots:
- The US FDA approval for Loqtorzi in combination with CT for 1L treatment and as monotherapy was based on P-III (JUPITER-02; n=289) & P-II (POLARIS-02) clinical trials on adults with metastatic or recurrent locally advanced NPC
- The results of P-III (JUPITER-02) demonstrated improved PFS, reducing the risk of progression of the disease by 48% & OS with a 37% death reduction rate vs CT alone whereas mOS was not reached with the combination therapy vs 33.7mos. in CT alone. The P-II (LOQTORZI) results showed an ORR of 20.5%, DCR of 40% & median OS of 17.4mos.
- Loqtorzi is an anti-PD-1 mAb that blocks PD-1 ligands PD-L1 & PD-L2 thereby activating the immune system and leading to the killing of tumors
Ref: Coherus | Image: Coherus
Related News:- Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
